United States

Vical Inc (VICL.OQ)

VICL.OQ on NASDAQ Stock Exchange Global Select Market

5 Dec 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for VICL.OQ


Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including... (more)


Beta: 2.00
Market Cap(Mil.): $30.28
Shares Outstanding(Mil.): 11.05
Dividend: --
Yield (%): --


  VICL.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -0.90 -- --
ROI: -17.86 -1.09 14.95
ROE: -17.95 -2.39 16.29

BRIEF-Vical reports Q3 loss per share $0.24

* Vical Inc says projecting net cash burn for 2016 between $8 million and $11 million

Nov 03 2016

BRIEF-Vical initiates phase 2 trial of HSV-2 therapeutic DNA vaccine

* Vical announces initiation of a phase 2 trial of its HSV 2 therapeutic DNA vaccine for genital herpes

Sep 26 2016

Astellas, Vical herpes vaccine fails mid-stage study

Japan's Astellas Pharma Inc and San Diego-based Vical Inc said their experimental herpes vaccine failed a mid-stage study involving certain kidney transplant patients.

Sep 19 2016

BRIEF-Vical and Astellas study on CMV vaccine fails to meet its primary endpoint

* Results from study demonstrated that trial did not meet its primary endpoint

Sep 19 2016

BRIEF-Anges MG to work together with Vical Incorporated on DNA vaccine business

* Says the company and Vical Incorporated has agreed to work together on DNA vaccine business, which includes research, development and manufacturing

Aug 12 2016

BRIEF-Vical Q2 loss per share $0.14

* Projecting net cash burn for 2016 between $8 million and $11 million Source text for Eikon: Further company coverage:

Aug 09 2016

BRIEF-Vical announces $7.8 mln equity investment by partner Anges MG

* Vical announces $7.8 million equity investment by partner, Anges MG

Aug 01 2016

BRIEF-AnGes MG to invest Vical and to hold 18.6 pct stake in it

* Says it to buy 1,841,420 shares of Vical Inc for $4.2448 per share on Aug. 3

Aug 01 2016

BRIEF-Vical's phase 1/2 trial data shows bivalent vaccine imparts reduction in genital herpes lesions durable to 9 months

* Initial top line 3-month data announced in june 2015 showed neither monovalent nor bivalent vaccine met primary endpoint of viral shedding rate reduction from baseline

Jun 20 2016


  Price Chg
Sanofi SA (SASY.PA) €74.58 -1.48
Novartis AG (NOVN.S) CHF69.30 -0.20
GlaxoSmithKline plc (GSK.L) 1,452.00p -7.00
AstraZeneca plc (AZN.L) 4,007.30p -26.00
Merck & Co., Inc. (MRK.N) $60.25 -0.88
Pfizer Inc. (PFE.N) $31.59 -0.04
Roche Holding Ltd. (ROG.S) CHF223.30 +1.20
Roche Holding Ltd. (RO.S) CHF226.20 +0.20
Genocea Biosciences Inc (GNCA.OQ) $3.89 --
Agenus Inc (AGEN.OQ) $4.31 +0.21

Earnings vs. Estimates